CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
25 hedge funds and large institutions have $3.33M invested in CASI Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
30% more capital invested
Capital invested by funds: $2.55M → $3.33M (+$777K)
0.02% more ownership
Funds ownership: 0.37% → 0.39% (+0.02%)
11% less funds holding
Funds holding: 28 → 25 (-3)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$375K |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
+$272K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$37.1K |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$20.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$18.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Moors & Cabot
Boston,
Massachusetts
|
-$72.6K |
| 2 |
PIM
Penobscot Investment Management
Boston,
Massachusetts
|
-$31K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$24.9K |
| 4 |
WJA
Williams Jones & Associates
New York
|
-$20K |
| 5 |
Renaissance Technologies
New York
|
-$16.4K |
CASI Hedge Fund Activity: Q1 2017 in Review
25 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2017, worth a combined $3.33M — up 30% from $2.55M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CASI positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $375K. The largest seller was Moors & Cabot, cutting an estimated $72.6K.
- 25 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2017, down from 28 in Q4 2016.
- Funds reported $3.33M of CASI Pharmaceuticals stock for Q1 2017, up 30% quarter-over-quarter.
- 3 funds opened new CASI Pharmaceuticals positions in Q1 2017 and 2 closed out, a net change of +1 holder.
- The largest CASI Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $375K added.
- The largest CASI Pharmaceuticals seller in Q1 2017 was Moors & Cabot, an estimated $72.6K sold.
Based on aggregated 13F filings for Q1 2017.